Abiopharma

🔍 MEHMEL ROBERT F (Executive)

Company: GRIFFON CORP (GFF)

Report Date: 2026-06-12

Detailed Transactions and Holdings:

• Sold 5,501 shares of Common Stock at $95.18 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 809,788.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,272 shares of Common Stock at $95.4 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 806,516.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-12 | Code: H | nature_of_ownership: by ESOP | shares_owned_after: 4,219.00

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $95.01 and $95.61, inclusive. The reporting person undertakes to provide Griffon Corporation, any security holder of Griffon Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares disposed of at each price within the ranges set forth in footnotes (1) and (2) to this Form 4.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.01 and $95.90, inclusive.